CATL Shares Fall as Hungary Plant Faces Safety Halt 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
OpenAI Rejects Apple Trade Secret Theft Claims 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., March 05, 2018 -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a live audio webcast and conference call on Monday, March 12, 2018 at the American College of Cardiology’s 67th Annual Scientific Session & Expo (ACC.18), following the presentation of new interim data from the ongoing ANNEXA-4 Phase 3b/4 trial of the Company’s investigational Factor Xa reversal agent andexanet alfa, during the Late-Breaking Clinical Trials Session.
The conference call and live audio webcast will be hosted by Dr. C. Michael Gibson, ANNEXA-4 Executive Committee member, Harvard Medical School professor and chairman of the PERFUSE Study Group, who will provide an overview of the interim results presented during the Late-Breaking Clinical Trials Session. Dr. Gibson will be joined by Portola management for the Q&A portion of the call.
| ANNEXA-4 Late-Breaking Oral Presentation Details | |
| Session: | (409) Late-Breaking Clinical Trials Session: Interventional Cardiology |
| Title: | ANNEXA-4: Interim Report on the ANNEXA-4 Study: Andexanet for Reversal of |
| Anticoagulation in Factor Xa-Associated Acute Major Bleeding | |
| Presenter: | Stuart J. Connolly, M.D., Professor Emeritus of Medicine, McMaster University, Hamilton |
| Health Sciences | |
| Date: | Monday, March 12, 10:45 a.m. – 11:45 a.m. ET |
| Room: | ACC.18 Main Tent, Hall C |
Webcast and Conference Call Details
To access the investor webcast and presentation slides on Monday, March 12 at 12:30 p.m. ET (9:30 a.m. PT), go to the Investor Relations section of the company’s website at http://investors.portola.com. The live call can be accessed by phone by dialing (844) 452-6828 The webcast can be accessed live on the Investor Relations section of the Company's website at http://investors.portola.com. It will be archived for 30 days following the call. from the United States and Canada or 1 (765) 507-2588 internationally and using the passcode 8493604. Analysts and investors interested in attending the in-peron event in Orlando should RSVP to Cara Miller at [email protected] for additional details.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact:
Cara Miller
Portola Pharmaceuticals
[email protected]
Media Contact:
Laurie Masonson
W2O Group
[email protected]
